-
Signature
-
/s/ Tae Sang Yoo, Attorney-in-Fact
-
Issuer symbol
-
BMRN
-
Transactions as of
-
19 May 2025
-
Net transactions value
-
-$164,961
-
Form type
-
4
-
Filing time
-
20 May 2025, 17:58:27 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Burkhart Erin |
GVP, Chief Accounting Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREEET, SAN RAFAEL |
/s/ Tae Sang Yoo, Attorney-in-Fact |
20 May 2025 |
0001927648 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BMRN |
Common Stock |
Tax liability |
$59,033 |
-996 |
-5.9% |
$59.27 |
15,959 |
19 May 2025 |
Direct |
|
| transaction |
BMRN |
Common Stock |
Sale |
$105,928 |
-1,786 |
-11% |
$59.31 |
14,173 |
20 May 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: